Mydecine Innovations Group Inc
Noveris Health Sciences Inc., a biotechnology company, engages in the research, development, and commercialization of psilocybin products to treat mental health conditions. The company primarily focuses on treating nicotine addiction and post-traumatic stress disorder. It also develops MYCO-005, MYCO-006, and MYCO-007 for MDMA and psilocybin analogs. The company has a partnership with Applied Pha… Read more
Market Cap & Net Worth: Mydecine Innovations Group Inc (MYCOF)
Mydecine Innovations Group Inc (PINK:MYCOF) has a market capitalization of $247.02K ($247.02K) as of March 19, 2026. Listed on the PINK stock exchange, this USA-based company holds position #38994 globally and #12683 in its home market, demonstrating a -20.00% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Mydecine Innovations Group Inc's stock price $0.00 by its total outstanding shares 61755385 (61.76 Million).
Mydecine Innovations Group Inc Market Cap History: 2015 to 2025
Mydecine Innovations Group Inc's market capitalization history from 2015 to 2025. Data shows change from $2.78 Billion to $247.02K (-65.25% CAGR).
Mydecine Innovations Group Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Mydecine Innovations Group Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
45412.01x
Mydecine Innovations Group Inc's market cap is 45412.01 times its annual revenue
1.00x
Higher than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $2.78 Billion | $84.00K | -$4.64 Million | 33083.61x | N/A |
| 2018 | $5.96 Billion | $207.66K | -$13.36 Million | 28706.27x | N/A |
| 2019 | $355.09 Million | $125.57K | -$3.73 Million | 2827.81x | N/A |
| 2020 | $1.08 Billion | $2.62K | -$26.95 Million | 412961.11x | N/A |
| 2021 | $340.27 Million | $7.49K | -$28.90 Million | 45412.01x | N/A |
Competitor Companies of MYCOF by Market Capitalization
Companies near Mydecine Innovations Group Inc in the global market cap rankings as of March 19, 2026.
Key companies related to Mydecine Innovations Group Inc by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #422 globally with a market cap of $51.61 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #432 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #452 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #719 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #422 | Zoetis Inc | NYSE:ZTS | $51.61 Billion | $117.35 |
| #432 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.31 |
| #452 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #719 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
Mydecine Innovations Group Inc Historical Marketcap From 2015 to 2025
Between 2015 and today, Mydecine Innovations Group Inc's market cap moved from $2.78 Billion to $ 247.02K, with a yearly change of -65.25%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $247.02K | -20.00% |
| 2024 | $308.78K | -66.67% |
| 2023 | $926.33K | -96.51% |
| 2022 | $26.55 Million | -92.20% |
| 2021 | $340.27 Million | -68.51% |
| 2020 | $1.08 Billion | +204.35% |
| 2019 | $355.09 Million | -94.04% |
| 2018 | $5.96 Billion | -82.84% |
| 2017 | $34.74 Billion | +177.78% |
| 2016 | $12.51 Billion | +350.00% |
| 2015 | $2.78 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 19th, 2026 the market cap of Mydecine Innovations Group Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $247.02K USD |
| MoneyControl | $247.02K USD |
| MarketWatch | $247.02K USD |
| marketcap.company | $247.02K USD |
| Reuters | $247.02K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.